Madiha Derouazi
CSO AC Immue
AC Immune
Lausanne, Switzerland
I shall be participating to the panelist at 4pm
About me
Dr. Madiha Derouazi is Chief Scientific offer at AC Immune in Lausanne, Switzerland since January 2024. AC Immune is a clinical-stage biopharmaceutical company in precision medicine to diagnose, treat and prevent neurodegenerative diseases. She joined from Speransa Therapeutics where she had been CEO since inception in 2021, leading development of a novel platform of prophylactic vaccines. Previously, she founded AMAL Therapeutics in 2012, an immuno-oncology company developing a new generation of therapeutic cancer vaccines and served as CEO and CSO of the company until 2022. Dr. Derouazi led AMAL’s acquisition by Boehringer Ingelheim for EUR 425 million in 2019. During her career, she has taken numerous biologicals and advanced therapy medicinal products from research through pre-clinical development and first-in-human clinical trials.
She holds a PhD in Cellular Biotechnology from the Swiss Federal Institute of Technology (EPFL) in Lausanne, which was followed by postdoctoral work concentrating on tumor immunology and vaccine development.
My organisation
Speaker sessions (1)
Tuesday, 10 December 2024
16:00 - 17:15
Keynotes and roundtable
Join the discussions on Staying Ahead: Harnessing the Power of the High-Tech Ecosystem for Competitive Advantage